世界の術後の鎮痛薬市場は、2025年に5234百万米ドルと算定されており、2026年には5478百万米ドルとなる見通しです。2026年から2032年の期間においては年平均成長率（CAGR）6.1%で推移し、2032年には7815百万米ドルに達すると予測されています。

本レポートは、術後の鎮痛薬メーカー、新規参入企業、および業界バリューチェーン全体の企業に対し、市場全体およびサブセグメント別の収益、生産量、平均価格に関する情報を、企業別、タイプ別、用途別、地域別に提供します。
世界の術後の鎮痛薬市場について、定量的・定性的分析を交えた包括的な概観を提供し、企業関係者が成長戦略の策定、競争環境の評価、現行市場における自社の位置付けの分析、術後の鎮痛薬に関する情報に基づいたビジネス判断を行うことを支援します。術後の鎮痛薬市場の規模、推定値及び予測値の観点から提示し、2025年を基準年として、2021年から2032年までの過去データ及び予測データを収録しております。

報告対象範囲
売上高・数量予測、企業シェア、競争環境、成長要因および市場トレンド

市場セグメンテーション
企業一覧
Mallinckrodt Pharmaceuticals (IE)
Pfizer (US)
Novartis (CH)
Eli Lilly (US)
Teva Pharmaceutical Industries (IL)
Bayer (DE)
Pacira BioSciences (US)
Trevena (US)
Vertex Pharmaceuticals (US)
Heron Therapeutics (US)
Nanjing Delova Biotech (CN)
Jiangsu Nhwa Pharmaceutical (CN)


タイプ別
Opioids
NSAIDs
Local Anesthetics
Tricyclic Antidepressants
Antiepileptic Drugs
Others


用途別
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others


製品カテゴリー


市場セグメント
Systemic
Regional

地域別
北米（アメリカ、カナダ、メキシコ）
欧州（ドイツ、フランス、イギリス、イタリアなど）
アジア太平洋（中国、日本、韓国、東南アジア、インドなど）
南米（ブラジルなど）
中東・アフリカ（トルコ、GCC諸国、アフリカなど）
本レポートは、世界の術後の鎮痛薬市場を包括的にセグメント化しております。地域別市場規模、タイプ別、用途別、企業別の市場規模も提供されます。より深い洞察を得るため、競争環境、主要競合他社、それぞれの市場順位をプロファイリングし、技術動向や新製品開発についても論じております。

本レポートの構成
第1章：術後の鎮痛薬の定義および調査範囲を明確化し、市場セグメント（タイプ別、用途別など）の概要を提示します。各セグメントの市場規模と将来の成長可能性を網羅し、現在の市場状況の概要を提供するとともに、短期・中期・長期の発展トレンドを分析します
第2章：術後の鎮痛薬メーカーの競争環境について、価格、生産量、価値ベースの市場シェア、最新の開発計画、合併・買収情報を含め詳細に分析します
第3章：術後の鎮痛薬の生産量／生産高および価値を地域・国別に検証し、今後6年間の各地域の市場規模と成長可能性について定量的な評価を提供します
第4章：地域および国レベルでの術後の鎮痛薬の消費動向を分析します。各地域および主要国における市場規模と成長可能性を定量化し、市場開発状況、見通し、対応可能な市場規模、国内生産量を概説します
第5章：術後の鎮痛薬に基づくタイプ別市場セグメントの構造を整理し、各セグメントの市場規模と成長ポテンシャルを明確化することで、企業・投資家によるブルーオーシャン機会の発見を支援します
第6章：用途別に術後の鎮痛薬の市場セグメントを整理し、各分野の市場規模、成長ポテンシャル、需要拡大余地を提示することで、下流市場における有望な参入機会や競争優位の確立に向けた判断材料を提供します
第7章：術後の鎮痛薬の主要プレイヤーを分析し、主要企業の基本情報（製品生産量／生産高、価値、価格、粗利益率、製品ポートフォリオ／新製品導入、最近の動向）を詳細に説明します
第8章：術後の鎮痛薬の上流および下流セグメントを含む業界バリューチェーンをレビューします
第9章：術後の鎮痛薬市場の動向と最新トレンドについて議論します。これには、メーカーにとっての推進要因、制約要因、課題、リスク、米国関税、関連政策分析が含まれます
第10章：主な調査結果と結論をまとめます
第11章：付録

The global Postoperative Pain Control Drug market was valued at US$ 5234 million in 2025 and is anticipated to reach US$ 7815 million by 2032, at a CAGR of 6.1% from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Postoperative Pain Control Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Postoperative Pain Control Drugs encompass a specialized class of acute-use pharmaceuticals formulated to suppress nociceptive (pain-sensing) signaling pathways following surgical trauma. Historically dominated by central nervous system (CNS) mu-opioid receptor agonists like morphine, fentanyl, and hydromorphone, modern postoperative pain protocols have radically shifted toward multimodal analgesia. This clinical strategy combines lower-dose opioids with diverse non-opioid mechanism families to maximize pain control while mitigating systemic side effects like respiratory depression, postoperative nausea and vomiting (PONV), and long-term dependency.

In 2025, global Postoperative Pain Control Drugs production reached approximately 414.08 million doses, with an average global market price of around US$ 12.64 per dose. And global Postoperative Pain Control Drugs production capacity reached approximately 540 million doses. The average gross margin in this industry reached 42.02%.

The supply chain for postoperative pain control drugs requires stringent chemical synthesis compliance, high-barrier sterile filling facilities, and specialized drug delivery carrier matrices. The upstream supply chain provides the foundational Active Pharmaceutical Ingredients (APIs), key chemical precursors, and advanced multi-phase delivery vehicles. Global life sciences chemical suppliers like Lonza Group and Siegfried Holding AG serve as critical upstream contract development and manufacturing organizations (CDMOs), synthesizing high-purity small molecule APIs under strict Current Good Manufacturing Practice (cGMP) regulations. For extended-release formulations, specialized polymer firms provide the upstream lipid matrices and bioresorbable poly(lactic-co-glycolic acid) (PLGA) microspheres required to encapsulate local anesthetics for multi-day local release. Concurrently, primary packaging giants like West Pharmaceutical Services, Inc. supply the critical upstream components, delivering the passivated elastomeric vial stoppers and sterile, ready-to-fill glass cartridges needed to ensure long-term formulation stability.

Conversely, the downstream supply chain spans specialty pharmaceutical innovators, generic drug manufacturers, sterile compounding operators, and institutional healthcare buyers. Major acute care pharmaceutical developers—such as Pacira BioSciences, Inc. (makers of Exparel), Heron Therapeutics, Inc. (Zynrelef), Vertex Pharmaceuticals (Journavx), and global injection specialists like Pfizer Inc. (Pfizer CentreOne)—operate as the primary downstream customers, purchasing raw upstream APIs and custom carrier vehicles to compound, sterilize, and package finished, hospital-ready analgesics. These finished clinical therapeutics are funneled downstream through Tier-1 pharmaceutical distributors including McKesson Corporation, AmerisourceBergen, and Cardinal Health. Ultimately, the vital final downstream enterprise end-users are acute care hospital networks (such as HCA Healthcare) and specialized ambulatory surgical centers (ASCs), which stock these fast-acting therapeutics in automated dispensing cabinets for surgical anesthesiologists and perioperative nursing teams to administer directly to patients entering post-anesthesia care units (PACU).

This report delivers a comprehensive overview of the global Postoperative Pain Control Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Postoperative Pain Control Drug. The Postoperative Pain Control Drug market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Postoperative Pain Control Drug market comprehensively. Regional market sizes by Type, by Application, by Dosage, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Postoperative Pain Control Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation
By Company
Mallinckrodt Pharmaceuticals (IE)
Pfizer (US)
Novartis (CH)
Eli Lilly (US)
Teva Pharmaceutical Industries (IL)
Bayer (DE)
Pacira BioSciences (US)
Trevena (US)
Vertex Pharmaceuticals (US)
Heron Therapeutics (US)
Nanjing Delova Biotech (CN)
Jiangsu Nhwa Pharmaceutical (CN)

Segment by Type
Opioids
NSAIDs
Local Anesthetics
Tricyclic Antidepressants
Antiepileptic Drugs
Others

Segment by Dosage
Intravenous
Oral
Others

Segment by Action Area
Systemic
Regional

by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Dosage, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Postoperative Pain Control Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Postoperative Pain Control Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

1 Postoperative Pain Control Drug Market Overview
1.1 Product Definition
1.2 Postoperative Pain Control Drug by Type
1.2.1 Global Postoperative Pain Control Drug Market Value by Type: 2025 vs 2032
1.2.2 Opioids
1.2.3 NSAIDs
1.2.4 Local Anesthetics
1.2.5 Tricyclic Antidepressants
1.2.6 Antiepileptic Drugs
1.2.7 Others
1.3 Postoperative Pain Control Drug by Dosage
1.3.1 Global Postoperative Pain Control Drug Market Value by Dosage: 2025 vs 2032
1.3.2 Intravenous
1.3.3 Oral
1.3.4 Others
1.4 Postoperative Pain Control Drug by Action Area
1.4.1 Global Postoperative Pain Control Drug Market Value by Action Area: 2025 vs 2032
1.4.2 Systemic
1.4.3 Regional
1.5 Postoperative Pain Control Drug by Application
1.5.1 Global Postoperative Pain Control Drug Market Value by Application: 2025 vs 2032
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.5.5 Others
1.6 Global Postoperative Pain Control Drug Market Size Estimates and Forecasts
1.6.1 Global Postoperative Pain Control Drug Revenue 2021–2032
1.6.2 Global Postoperative Pain Control Drug Sales 2021–2032
1.6.3 Global Postoperative Pain Control Drug Market Average Price (2021–2032)
1.7 Assumptions and Limitations

2 Postoperative Pain Control Drug Market Competition by Manufacturers
2.1 Global Postoperative Pain Control Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Postoperative Pain Control Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Postoperative Pain Control Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Postoperative Pain Control Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Postoperative Pain Control Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Postoperative Pain Control Drug, Product Types and Applications
2.7 Global Key Manufacturers of Postoperative Pain Control Drug, Date of Entry into the Industry
2.8 Global Postoperative Pain Control Drug Market Competitive Situation and Trends
2.8.1 Global Postoperative Pain Control Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Postoperative Pain Control Drug Players Market Share by Revenue
2.8.3 Global Postoperative Pain Control Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Postoperative Pain Control Drug Market Scenario by Region
3.1 Global Postoperative Pain Control Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Postoperative Pain Control Drug Sales by Region: 2021–2032
3.2.1 Global Postoperative Pain Control Drug Sales by Region: 2021–2026
3.2.2 Global Postoperative Pain Control Drug Sales by Region: 2027–2032
3.3 Global Postoperative Pain Control Drug Revenue by Region: 2021–2032
3.3.1 Global Postoperative Pain Control Drug Revenue by Region: 2021–2026
3.3.2 Global Postoperative Pain Control Drug Revenue by Region: 2027–2032
3.4 North America Postoperative Pain Control Drug Market Facts & Figures by Country
3.4.1 North America Postoperative Pain Control Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Postoperative Pain Control Drug Sales by Country (2021–2032)
3.4.3 North America Postoperative Pain Control Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Postoperative Pain Control Drug Market Facts & Figures by Country
3.5.1 Europe Postoperative Pain Control Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Postoperative Pain Control Drug Sales by Country (2021–2032)
3.5.3 Europe Postoperative Pain Control Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Postoperative Pain Control Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Postoperative Pain Control Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Postoperative Pain Control Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Postoperative Pain Control Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Postoperative Pain Control Drug Market Facts & Figures by Country
3.7.1 Latin America Postoperative Pain Control Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Postoperative Pain Control Drug Sales by Country (2021–2032)
3.7.3 Latin America Postoperative Pain Control Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Postoperative Pain Control Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Postoperative Pain Control Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Postoperative Pain Control Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Postoperative Pain Control Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE

4 Segment by Type
4.1 Global Postoperative Pain Control Drug Sales by Type (2021–2032)
4.1.1 Global Postoperative Pain Control Drug Sales by Type (2021–2026)
4.1.2 Global Postoperative Pain Control Drug Sales by Type (2027–2032)
4.1.3 Global Postoperative Pain Control Drug Sales Market Share by Type (2021–2032)
4.2 Global Postoperative Pain Control Drug Revenue by Type (2021–2032)
4.2.1 Global Postoperative Pain Control Drug Revenue by Type (2021–2026)
4.2.2 Global Postoperative Pain Control Drug Revenue by Type (2027–2032)
4.2.3 Global Postoperative Pain Control Drug Revenue Market Share by Type (2021–2032)
4.3 Global Postoperative Pain Control Drug Price by Type (2021–2032)

5 Segment by Application
5.1 Global Postoperative Pain Control Drug Sales by Application (2021–2032)
5.1.1 Global Postoperative Pain Control Drug Sales by Application (2021–2026)
5.1.2 Global Postoperative Pain Control Drug Sales by Application (2027–2032)
5.1.3 Global Postoperative Pain Control Drug Sales Market Share by Application (2021–2032)
5.2 Global Postoperative Pain Control Drug Revenue by Application (2021–2032)
5.2.1 Global Postoperative Pain Control Drug Revenue by Application (2021–2026)
5.2.2 Global Postoperative Pain Control Drug Revenue by Application (2027–2032)
5.2.3 Global Postoperative Pain Control Drug Revenue Market Share by Application (2021–2032)
5.3 Global Postoperative Pain Control Drug Price by Application (2021–2032)

6 Key Companies Profiled
6.1 Mallinckrodt Pharmaceuticals (IE)
6.1.1 Mallinckrodt Pharmaceuticals (IE) Company Information
6.1.2 Mallinckrodt Pharmaceuticals (IE) Description and Business Overview
6.1.3 Mallinckrodt Pharmaceuticals (IE) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Mallinckrodt Pharmaceuticals (IE) Postoperative Pain Control Drug Product Portfolio
6.1.5 Mallinckrodt Pharmaceuticals (IE) Recent Developments/Updates
6.2 Pfizer (US)
6.2.1 Pfizer (US) Company Information
6.2.2 Pfizer (US) Description and Business Overview
6.2.3 Pfizer (US) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer (US) Postoperative Pain Control Drug Product Portfolio
6.2.5 Pfizer (US) Recent Developments/Updates
6.3 Novartis (CH)
6.3.1 Novartis (CH) Company Information
6.3.2 Novartis (CH) Description and Business Overview
6.3.3 Novartis (CH) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Novartis (CH) Postoperative Pain Control Drug Product Portfolio
6.3.5 Novartis (CH) Recent Developments/Updates
6.4 Eli Lilly (US)
6.4.1 Eli Lilly (US) Company Information
6.4.2 Eli Lilly (US) Description and Business Overview
6.4.3 Eli Lilly (US) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Eli Lilly (US) Postoperative Pain Control Drug Product Portfolio
6.4.5 Eli Lilly (US) Recent Developments/Updates
6.5 Teva Pharmaceutical Industries (IL)
6.5.1 Teva Pharmaceutical Industries (IL) Company Information
6.5.2 Teva Pharmaceutical Industries (IL) Description and Business Overview
6.5.3 Teva Pharmaceutical Industries (IL) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Teva Pharmaceutical Industries (IL) Postoperative Pain Control Drug Product Portfolio
6.5.5 Teva Pharmaceutical Industries (IL) Recent Developments/Updates
6.6 Bayer (DE)
6.6.1 Bayer (DE) Company Information
6.6.2 Bayer (DE) Description and Business Overview
6.6.3 Bayer (DE) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Bayer (DE) Postoperative Pain Control Drug Product Portfolio
6.6.5 Bayer (DE) Recent Developments/Updates
6.7 Pacira BioSciences (US)
6.7.1 Pacira BioSciences (US) Company Information
6.7.2 Pacira BioSciences (US) Description and Business Overview
6.7.3 Pacira BioSciences (US) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Pacira BioSciences (US) Postoperative Pain Control Drug Product Portfolio
6.7.5 Pacira BioSciences (US) Recent Developments/Updates
6.8 Trevena (US)
6.8.1 Trevena (US) Company Information
6.8.2 Trevena (US) Description and Business Overview
6.8.3 Trevena (US) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Trevena (US) Postoperative Pain Control Drug Product Portfolio
6.8.5 Trevena (US) Recent Developments/Updates
6.9 Vertex Pharmaceuticals (US)
6.9.1 Vertex Pharmaceuticals (US) Company Information
6.9.2 Vertex Pharmaceuticals (US) Description and Business Overview
6.9.3 Vertex Pharmaceuticals (US) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Vertex Pharmaceuticals (US) Postoperative Pain Control Drug Product Portfolio
6.9.5 Vertex Pharmaceuticals (US) Recent Developments/Updates
6.10 Heron Therapeutics (US)
6.10.1 Heron Therapeutics (US) Company Information
6.10.2 Heron Therapeutics (US) Description and Business Overview
6.10.3 Heron Therapeutics (US) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Heron Therapeutics (US) Postoperative Pain Control Drug Product Portfolio
6.10.5 Heron Therapeutics (US) Recent Developments/Updates
6.11 Nanjing Delova Biotech (CN)
6.11.1 Nanjing Delova Biotech (CN) Company Information
6.11.2 Nanjing Delova Biotech (CN) Description and Business Overview
6.11.3 Nanjing Delova Biotech (CN) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Nanjing Delova Biotech (CN) Postoperative Pain Control Drug Product Portfolio
6.11.5 Nanjing Delova Biotech (CN) Recent Developments/Updates
6.12 Jiangsu Nhwa Pharmaceutical (CN)
6.12.1 Jiangsu Nhwa Pharmaceutical (CN) Company Information
6.12.2 Jiangsu Nhwa Pharmaceutical (CN) Description and Business Overview
6.12.3 Jiangsu Nhwa Pharmaceutical (CN) Postoperative Pain Control Drug Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Jiangsu Nhwa Pharmaceutical (CN) Postoperative Pain Control Drug Product Portfolio
6.12.5 Jiangsu Nhwa Pharmaceutical (CN) Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis
7.1 Postoperative Pain Control Drug Industry Chain Analysis
7.2 Postoperative Pain Control Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Postoperative Pain Control Drug Production Mode & Process Analysis
7.4 Postoperative Pain Control Drug Sales and Marketing
7.4.1 Postoperative Pain Control Drug Sales Channels
7.4.2 Postoperative Pain Control Drug Distributors
7.5 Postoperative Pain Control Drug Customer Analysis

8 Postoperative Pain Control Drug Market Dynamics
8.1 Postoperative Pain Control Drug Industry Trends
8.2 Postoperative Pain Control Drug Market Drivers
8.3 Postoperative Pain Control Drug Market Challenges
8.4 Postoperative Pain Control Drug Market Restraints
8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer